Lilly, Boehringer Collaborate on Diabetes Drugs

INDIANAPOLIS -- Eli Lilly and Co. will pay Boehringer Ingelheim $387.4 million and work with the German drugmaker in a diabetes drug collaboration that could lead to more than $1 billion in future payments for the U.S. pharmaceutical company.

Lilly, based in Indianapolis, and Boehringer Ingelheim will focus on treatments in mid- and late-stage clinical development. That includes two Lilly insulins expected to enter late-stage testing this year and two treatments from the German firm.

Boehringer Ingelheim also has an option to work with Lilly on another potential treatment in mid-stage testing. It will be eligible for milestone payments totaling 625 million euros. Lilly could receive milestone payments of up to $650 million plus an additional $525 million if Boehringer Ingelheim takes the option for the third Lilly drug.

(Copyright 2011 by The Associated Press. All Rights Reserved.)


More Stories

Don't Miss

  • Community Calendar
    Copyright 2017 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
  • Connect with 8 News NOW
    Copyright 2017 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
  • Deadly Dust: Asbestos
    Copyright 2017 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
  • Community Pride
    Copyright 2017 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
  • Politics Now
    Copyright 2017 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Latest News

Video Center